Please login to the form below

Unlicensed Avastin

This page shows the latest Unlicensed Avastin news and features for those working in and with pharma, biotech and healthcare.

of rows over unlicensed use of Avastin in AMD. ... Switching to off-licence Avastin would save £100m or more, if applied across the whole of England.

NHS wins legal fight with pharma over off-label Avastin

A group of NHS organisations have claimed a legal victory against Bayer and Novartis, which had sought to stop them using Avastin as a cheap, unlicensed substitute for their ophthalmology drugs. ... The case could not only open the door for more

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...